Mizuho lowered the firm’s price target on ResMed to $160 from $180 and keeps a Buy rating on the shares. The company posted a “mixed headline print,” with the stock falling 10% on a sizable Flow Gen miss, which the company chalked up to tough comps despite intra-quarter noise of GLP-1 slippage, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RMD: